Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. As a result, API syntheses are growing longer and, at times, undermining drug sponsors’ speed-to-clinic. These longer synthetic pathways present challenges for process chemists hoping to achieve an efficient API manufacturing process, due to factors such as elaborate raw material needs and supply chain obstacles.

These compounding layers can delay start times and extend preclinical development. To help mitigate these issues for sponsors, Lonza Small Molecules has partnered with Elsevier Information Systems to leverage a synthesis planning and route scouting solution that combines Lonza’s intellectual property (IP) with Elsevier’s AI-enabled route design technology – Reaxys predictive retrosynthesis.

Download the white paper to learn more about using synthesis and route design technology to approach API complexity. 

You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center